Related Experiment Video
Updated: Dec 10, 2025
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.0K
5-Fluorouracil Conversion Pathway Mutations in Gastric Cancer
Alessio Biagioni1, Fabio Staderini2, Sara Peri2
1Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale G.B. Morgagni 50, 50134 Firenze, Italy.
Biology
|September 5, 2020
Summary
Genetic mutations in 5-Fluorouracil (5FU) pathways are linked to poor gastric cancer prognosis. Understanding these genetic variations, like TYMP deletions and TYMS amplifications, is crucial for improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Pharmacogenomics
- Cancer Genetics
Background:
- 5-Fluorouracil (5FU) is a cornerstone chemotherapy agent, yet chemoresistance and treatment failure remain significant challenges in gastric cancer (GC).
- Genetic variations significantly influence GC prognosis and treatment response, particularly between Asian and Caucasian populations.
- The genetic heterogeneity of GC necessitates detailed investigation into the 5FU metabolic pathway.
Purpose of the Study:
- To investigate the impact of mutations in the 5FU conversion and activation pathways on gastric cancer prognosis.
- To identify specific genetic alterations associated with chemoresistance and reduced overall survival in GC patients.
Main Methods:
- Utilized cBioPortal software to analyze a comprehensive database of clinical and whole-genome studies.
- Evaluated genetic alterations in key components of the three major 5FU transformation pathways.
- Correlated identified mutations with patient prognosis and overall survival data.
Main Results:
- Mutations within the 5FU metabolic pathways were significantly associated with poorer prognosis and decreased overall survival in GC.
- Specific genetic alterations, including deletions in the Thymidine phosphorylase (TYMP) gene and amplifications in the Thymidylate synthase (TYMS) gene, were frequently observed.
- These findings highlight the role of genetic variations in 5FU efficacy.
Conclusions:
- Genetic mutations in 5FU metabolic pathways are critical determinants of treatment outcomes in gastric cancer.
- Targeting specific genetic alterations and exploring strategies like prodrugs and dihydropyrimidine dehydrogenase (DPD) inhibitors may enhance 5FU-based chemotherapy.
- Further research is needed to develop tailored therapies for chemoresistant GC with high genomic instability.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
12:13Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae
Published on: April 5, 2015
10.7K
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
5.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.6K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.1K
01:33Cancer-Critical Genes I: Proto-oncogenes
10.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.8K
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
01:25Mutagenicity and Carcinogenicity
1.7K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K